Related references
Note: Only part of the references are listed.Implementation of medical retina virtual clinics in a tertiary eye care referral centre
Karsten Kortuem et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2018)
Treat-and-Extend versus Monthly Regimen in Neovascular Age-Related Macular Degeneration Results with Ranibizumab from the TREND Study
Rufino Silva et al.
OPHTHALMOLOGY (2018)
Real-world outcomes in patients with neovascular age-related macular degeneration treated with intravitreal vascular endothelial growth factor inhibitors
Hemal Mehta et al.
PROGRESS IN RETINAL AND EYE RESEARCH (2018)
VISUAL ACUITY IMPROVEMENT WHEN SWITCHING FROM RANIBIZUMAB TO AFLIBERCEPT IS NOT SUSTAINED
Cecilia S. Lee et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2018)
Switching between ranibizumab and aflibercept for the treatment of neovascular age-related macular degeneration
Irmela Mantel et al.
SURVEY OF OPHTHALMOLOGY (2018)
Topical antibiotics and intravitreal injections
Alex P. Hunyor et al.
ACTA OPHTHALMOLOGICA (2018)
Ranibizumab treatment history as predictor of the switch-response to aflibercept: evidence for drug tolerance
Ali Dirani et al.
CLINICAL OPHTHALMOLOGY (2018)
A view of the current and future role of optical coherence tomography in the management of age-related macular degeneration
U. Schmidt-Erfurth et al.
EYE (2017)
One-year real-world outcomes in patients receiving fixed-dosing aflibercept for neovascular age related macular degeneration
H. Almuhtaseb et al.
EYE (2017)
Appropriateness of quality standards for meaningful intercentre comparisons of aflibercept service provision for neovascular age-related macular degeneration
J. S. Talks et al.
EYE (2017)
A systematic review to assess the 'treat-and-extend' dosing regimen for neovascular age-related macular degeneration using ranibizumab
S. R. Rufai et al.
EYE (2017)
Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti-vascular endothelial growth factor therapy of macular diseases
Paolo Lanzetta et al.
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2017)
Bilateral Neovascular Age-Related Macular Degeneration: Comparisons between First and Second Eyes
Jamie K. Chew et al.
OPHTHALMOLOGICA (2017)
The Current State of Teleophthalmology in the United States
Siddarth Rathi et al.
OPHTHALMOLOGY (2017)
Investigation of time to first presentation and extrahospital factors in the treatment of neovascular age-related macular degeneration: a retrospective cross-sectional study
Peng Yong Sim et al.
BMJ OPEN (2017)
Evaluating Effects of Switching Anti-Vascular Endothelial Growth Factor Drugs for Age-Related Macular Degeneration and Diabetic Macular Edema
Frederick L. Ferris et al.
JAMA OPHTHALMOLOGY (2017)
Aflibercept treatment for neovascular AMD beyond the first year: consensus recommendations by a UK expert roundtable panel, 2017 update
Praveen J. Patel et al.
CLINICAL OPHTHALMOLOGY (2017)
Polypoidal choroidal vasculopathy: a common type of neovascular age-related macular degeneration in Caucasians
Sohraab Yadav et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2017)
Experience of Anti-VEGF Treatment and Clinical Levels of Depression and Anxiety in Patients With Wet Age-Related Macular Degeneration
Hugo Senra et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2017)
Switching to aflibercept among patients with treatment-resistant neovascular age-related macular degeneration: a systematic review with meta-analysis
Kimberly Spooner et al.
CLINICAL OPHTHALMOLOGY (2017)
The concept of virtual clinics in monitoring patients with age-related macular degeneration
Konstantinos T. Tsaousis et al.
ACTA OPHTHALMOLOGICA (2016)
Ranibizumab for the treatment of wet AMD: a summary of real-world studies
V. Chong
EYE (2016)
Defining a Minimum Set of Standardized Patient-centered Outcome Measures for Macular Degeneration
Ian A. Rodrigues et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2016)
UK Neovascular Age-Related Macular Degeneration Database. Report 6: time to retreatment after a pause in therapy. Outcomes from 92 976 intravitreal ranibizumab injections
Krishnappa C. Madhusudhana et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2016)
Effects of switching from ranibizumab to aflibercept in eyes with exudative age-related macular degeneration
Daniel Barthelmes et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2016)
The UK Neovascular AMD Database Report 3: inter-centre variation in visual acuity outcomes and establishing real-world measures of care
G. Liew et al.
EYE (2016)
Leading causes of certifiable visual loss in England and Wales during the year ending 31 March 2013
A. Quartilho et al.
EYE (2016)
Effectiveness of UK optometric enhanced eye care services: a realist review of the literature
Helen Baker et al.
OPHTHALMIC AND PHYSIOLOGICAL OPTICS (2016)
Characteristics and Predictors of Early and Delayed Responders to Ranibizumab Treatment in Neovascular Age-Related Macular Degeneration: A Retrospective Analysis from the ANCHOR, MARINA, HARBOR, and CATT Trials
Richard Gale et al.
OPHTHALMOLOGICA (2016)
Treatment Patterns and Visual Outcomes during the Maintenance Phase of Treat-and-Extend Therapy for Age-Related Macular Degeneration
Rohan W. Essex et al.
OPHTHALMOLOGY (2016)
METAANALYSIS OF REAL-WORLD OUTCOMES OF INTRAVITREAL RANIBIZUMAB FOR THE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Leah N. Kim et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2016)
INTRAVITREAL AFLIBERCEPT FOR CHOROIDAL NEOVASCULARIZATION DUE TO AGE-RELATED MACULAR DEGENERATION UNRESPONSIVE TO RANIBIZUMAB THERAPY
Valentina Sarao et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2016)
Effectiveness of Community versus Hospital Eye Service follow-up for patients with neovascular age-related macular degeneration with quiescent disease (ECHoES): a virtual non-inferiority trial
Barnaby C. Reeves et al.
BMJ OPEN (2016)
A Meta-Analysis of Studies Evaluating Visual and Anatomical Outcomes in Patients with Treatment Resistant Neovascular Age-Related Macular Degeneration following Switching to Treatment with Aflibercept
Sophie Seguin-Greenstein et al.
JOURNAL OF OPHTHALMOLOGY (2016)
UK AMD EMR USERS GROUP REPORT V: benefits of initiating ranibizumab therapy for neovascular AMD in eyes with vision better than 6/12
Aaron Y. Lee et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2015)
Long-term visual outcomes of intravitreal ranibizumab treatment for wet age-related macular degeneration and effect on blindness rates in south-east Scotland
S. Borooah et al.
EYE (2015)
Defining response to anti-VEGF therapies in neovascular AMD
W. M. Amoaku et al.
EYE (2015)
Improving patient access to prevent sight loss: ophthalmic electronic referrals and communication (Scotland)
A. A. Khan et al.
PUBLIC HEALTH (2015)
SUSTAINED ELEVATION OF INTRAOCULAR PRESSURE AFTER INTRAVITREAL ANTI-VEGF AGENTS What Is the Evidence?
Vaidehi S. Dedania et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2015)
Health professionals' and service users' perspectives of shared care for monitoring wet age-related macular degeneration: a qualitative study alongside the ECHoES trial
D. Townsend et al.
BMJ OPEN (2015)
The cost-effectiveness of initiating ranibizumab therapy in eyes with neovascular AMD with good vision: an economic model using real-world outcomes
Thomas Butt et al.
BMJ OPEN (2015)
Repeated Intravitreous Ranibizumab Injections for Diabetic Macular Edema and the Risk of Sustained Elevation of Intraocular Pressure or the Need for Ocular Hypotensive Treatment
Susan B. Bressler et al.
JAMA OPHTHALMOLOGY (2015)
Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration
Frank G. Holz et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2015)
Utilisation of orthoptists to give intravitreal injections-a multidisciplinary approach
S. P. Mall et al.
EYE (2015)
The accuracy of home monitoring to detect disease activity during maintenance therapy for neovascular ARMD
Martin McKibbin et al.
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2015)
Rate of vision loss in neovascular age-related macular degeneration explored
Juan P. Real et al.
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2015)
Consequences of long-term discontinuation of vascular endothelial growth factor inhibitor therapy in the patients with neovascular age-related macular degeneration
Anagha Vaze et al.
ACTA OPHTHALMOLOGICA (2014)
Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA)
Ursula Schmidt-Erfurth et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2014)
Diagnostic accuracy of the Amsler grid and the preferential hyperacuity perimetry in the screening of patients with age-related macular degeneration: systematic review and meta-analysis
L. Faes et al.
EYE (2014)
Short-term intraocular pressure trends following intravitreal ranibizumab injections for neovascular age-related macular degeneration-the role of oral acetazolamide in protecting glaucoma patients
C. D. Murray et al.
EYE (2014)
Switch of anti-VEGF agents is an option for nonresponders in the treatment of AMD
C. Ehlken et al.
EYE (2014)
Implementation of a nurse-delivered intravitreal injection service
J. DaCosta et al.
EYE (2014)
The Neovascular Age-Related Macular Degeneration Database: Multicenter Study of 92 976 Ranibizumab Injections
Adnan Tufail et al.
OPHTHALMOLOGY (2014)
The Neovascular Age-Related Macular Degeneration Database Report 2: Incidence, Management, and Visual Outcomes of Second Treated Eyes
Javier Zarranz-Ventura et al.
OPHTHALMOLOGY (2014)
Which visual acuity measurements define high-quality care for patients with neovascular age-related macular degeneration treated with ranibizumab?
A. H. Ross et al.
EYE (2013)
Seven-Year Outcomes in Ranibizumab-Treated Patients in ANCHOR, MARINA, and HORIZON
Soraya Rofagha et al.
OPHTHALMOLOGY (2013)
Time Trends in the Incidence and Causes of Blindness in Israel
Alon Skaat et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2012)
Incidence of Legal Blindness From Age-Related Macular Degeneration in Denmark: Year 2000 to 2010
Sara Brandi Bloch et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2012)
The estimated prevalence and incidence of late stage age related macular degeneration in the UK
Christopher G. Owen et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2012)
Visual impairment certification secondary to ARMD in Leeds, 2005-2010: is the incidence falling?
E. Rostron et al.
EYE (2012)
Combined OCT and colour fundus photography in virtual clinic assessments of wet AMD patients
M. Mookhtiar et al.
EYE (2012)
Action on AMD. Optimising patient management: act now to ensure current and continual delivery of best possible patient care
W. Amoaku et al.
EYE (2012)
Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration
Jeffrey S. Heier et al.
OPHTHALMOLOGY (2012)
Delay between medical indication to anti-VEGF treatment in age-related macular degeneration can result in a loss of visual acuity
Philipp Sebastian Muether et al.
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2011)
Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration The CATT Research Group
Daniel F. Martin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Age-Related Macular Degeneration and Risk Factors for the Development of Choroidal Neovascularisation in the Fellow Eye: A 3-Year Follow-Up Study
Rufino Silva et al.
OPHTHALMOLOGICA (2011)
Teleophthalmology with optical coherence tomography imaging in community optometry. Evaluation of a quality improvement for macular patients
Simon P. Kelly et al.
CLINICAL OPHTHALMOLOGY (2011)
Ranibizumab for neovascular age-related macular degeneration
Philip J. Rosenfeld et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Ranibizumab versus verteporfin for neovascular age-related macular degeneration
David M. Brown et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Share Paper
